BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Tuesday, May 14, 2024
Home
»
Newsletters
» BioWorld Science
BioWorld Science
March 28, 2006
View Archived Issues
Genta and Emisphere sign licensing agreement for oral gallium compound
Read More
Enrollment completed in phase II solid tumor study of CA4P with chemotherapy
Read More
Grip strength measurements improve in BioAstin tendonitis study
Read More
Noxxon and Pfizer form Spiegelmer product alliance
Read More
Pharming to acquire DNage
Read More
Reata advances RTA-402 into clinical testing
Read More
Paion begins program for next-generation plasminogen activators
Read More
Mimetogen completes Series A financing, new licensing agreement
Read More
Bioaccelerate Holdings to change name, spin off subsidiaries
Read More
Positive opinion handed down in Europe for Ganfort
Read More
Exenatide LAR studied for type 2 diabetes in new study
Read More
Opposing trends in Oncophage renal cancer phase III trial
Read More
CHMP recommends against approval of Zelnorm for IBS-C in Europe
Read More
Phase II data for ALGRX-4975 in hernia repair at odds with other phase II results
Read More
New dosages of Risperdal M-TAB now available
Read More
Rectogesic completes E.U. mutual recognition procedure
Read More
Novel calcium-sensing receptor antagonist promotes PTH release in vivo
Read More
Affibody molecules -- a tool for preclinical drug profiling
Read More
Inhibitors of 11beta-HSD1: candidates for the treatment of obesity, diabetes and metabolic syndrome
Read More
Lyrica receives European approval for GAD
Read More
Aranesp approved for every-three-week dosing
Read More
New treatment options for cancer covered in recent patents
Read More
Cubist responds to approvable letter for Cubicin
Read More
Data on new chemokine CXC receptor antagonists reported at ACS meeting
Read More
Preclinical data on the antidiabetic compound SYR-322 presented
Read More
A novel target to improve memory: ghrelin
Read More